Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Arlandis-Guzman S, Errando-Smet C, Trocio J, Arumi D, Rejas J.

BMC Urol. 2011 May 20;11:9. doi: 10.1186/1471-2490-11-9.

3.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

4.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

5.

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.

Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J.

Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Epub 2008 Jun 18.

PMID:
18565239
6.

Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ.

Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review.

PMID:
24567280
7.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
8.

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

9.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
10.

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.

Sicras-Mainar A, Rejas J, Navarro-Artieda R, Aguado-Jodar A, Ruiz-Torrejón A, Ibáñez-Nolla J, Kvasz M.

BMC Urol. 2013 Oct 21;13:51. doi: 10.1186/1471-2490-13-51.

11.

Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.

Pradelli L, Iannazzo S.

J Med Econ. 2009 Mar;12(1):25-35. doi: 10.3111/13696990902767800.

PMID:
19450062
12.

Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Aguado-Jodar A, Ruíz-Torrejón A.

Actas Urol Esp. 2014 Oct;38(8):530-7. doi: 10.1016/j.acuro.2014.02.001. Epub 2014 Mar 12. English, Spanish.

PMID:
24630426
13.

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.

Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.

J Manag Care Spec Pharm. 2016 Sep;22(9):1072-84. doi: 10.18553/jmcp.2016.22.9.1072.

14.

Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, Sáez-Zafra M, Coll-de Tuero G.

Clin Drug Investig. 2015 Dec;35(12):795-805. doi: 10.1007/s40261-015-0342-2.

PMID:
26464261
15.

Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.

Armstrong EP, Malone DC, Bui CN.

J Med Econ. 2012;15 Suppl 1:35-44. doi: 10.3111/13696998.2012.732635. Epub 2012 Oct 8.

PMID:
22998646
16.

Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.

Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S.

Value Health. 2015 Sep;18(6):783-90. doi: 10.1016/j.jval.2015.05.011. Epub 2015 Sep 9.

17.

Impact of fesoterodine on quality of life: pooled data from two randomized trials.

Kelleher CJ, Tubaro A, Wang JT, Kopp Z.

BJU Int. 2008 Jul;102(1):56-61. doi: 10.1111/j.1464-410X.2008.07710.x.

18.

Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.

Chen HW, Bercik RS, Werner EF, Thung SF.

J Urol. 2012 Jan;187(1):178-84. doi: 10.1016/j.juro.2011.09.052. Epub 2011 Nov 17.

PMID:
22100006
19.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
20.

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.

Ko Y, Malone DC, Armstrong EP.

Pharmacotherapy. 2006 Dec;26(12):1694-702.

PMID:
17125433

Supplemental Content

Support Center